<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2020-04106-645-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">Betydelsen av lungans microbiome hos individer med biomass-orsakad kroniskt obstruktiv lungsjukdom</narrative>
   <narrative xml:lang="EN">Understanding the role of lung microbiome in biomass smoke exposure related chronic obstructive pulmonary disease</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Biomass smoke (BMS) exposure is a greater global risk factor for chronic obstructive pulmonary disease (COPD) compared to tobacco smoking (TBS). Women living in the rural areas of Low-and Middle-Income countries are disproportionately affected by BMS induced COPD as they cook for 4-6h/day using biomass fuel. Earlier lung was considered as sterile. With emerging evidence, the presence of normal lung microbiome and its role in maintaining homeostasis as well as in disease conditions is being realized. Alteration of normal lung microbiome may predispose individuals to chronic lung diseases. Changes in microbial diversity associated with asthma, cystic fibrosis, COPD, have been shown. However, limited information is available on lung microbial dysbiosis in TBS induced COPD patients and almost no information on lung microbiome of BMS induced COPD subjects is available at present. Hence, with a multi-national team, which includes researchers, clinicians and microbiologist we aim to compare the lung microbiome from induced sputum among BMS exposed women with COPD, BMS exposed women without COPD and healthy non-BMS exposed women (n= 50/group: 2021-early 2022). Molecular microbiological techniques such as high throughput amplicon sequencing of 16S rRNA genes will be used to analyze the data (Fall 2021-Fall 2022). We will initiate two-year continuous collaborative work between Sweden, India and Germany (2021-2022) with the aim of developing joint long-term research network and project.</narrative>
   <narrative xml:lang="SV">Exponering f&#xF6;r biomassr&#xF6;k orsakar utvecklande av kroniskt obstruktiv lungsjukdom (KOL) och drabbar fler m&#xE4;nniskor globalt j&#xE4;mf&#xF6;rt med tobaksr&#xF6;ksexponering. Antalet som exponeras f&#xF6;r biomassr&#xF6;k i hemmet utg&#xF6;r 3 miljarder att j&#xE4;mf&#xF6;ras med 1,1 miljarder r&#xF6;kare globalt. Runt 50% av alla hush&#xE5;ll globalt och 90% av hush&#xE5;llen p&#xE5; landsbygden i l&#xE5;g- och medelinkomstl&#xE4;nder anv&#xE4;nder sig av f&#xF6;rbr&#xE4;nning av biomassa, som sin huvudsakliga energik&#xE4;lla. Under 2015, orsakades 3,2 miljoner av d&#xF6;dsfallen i v&#xE4;rlden av KOL och utgjorde 2.6% av de globalt funktionsjusterade f&#xF6;rlorade levnads&#xE5;ren (DALYs). I nul&#xE4;get utg&#xF6;r KOL den 3:e vanligaste d&#xF6;dsorsaken globalt. Runt 90 % av de som utvecklat KOL bor i l&#xE5;g- och medelinkomstl&#xE4;nder. Hittills har KOL-forskning bedrivits i h&#xF6;ginkomstl&#xE4;nder med fokus p&#xE5; tobaksorsakad KOL. Det &#xE4;r d&#xE4;rf&#xF6;r p&#xE5;tagligt att kunskap saknas r&#xF6;rande KOL i allm&#xE4;nhet men s&#xE4;rskilt biomass-orsakad KOL hos individer i l&#xE5;g- och medelinkomstl&#xE4;nder inklusive Indien. Tidigare har man ansett att milj&#xF6;n i lungan &#xE4;r steril. Man har p&#xE5; senare &#xE5;r f&#xE5;tt ompr&#xF6;va detta d&#xE5; man med k&#xE4;nsligare metodik lyckats kartl&#xE4;gga f&#xF6;rekomsten av lungans microorganismer, som anses ha stor betydels f&#xF6;r att uppr&#xE4;tth&#xE5;lla homeostas. Moderna molekyl&#xE4;ra mikrobiologiska tekniker (som &#x201D;high throughput amplicon sequencing of 16S rRNA genes&#x201D;) har anv&#xE4;nts i ett flertal studier f&#xF6;r att kartl&#xE4;gga lungans microbiota, vilka p&#xE5;visat f&#xF6;r&#xE4;ndringar i microbiomet vid sjukdomar som astma, tobaksinducerad KOL och cystisk fibros (CF). Hos patienter med CF har man f&#xF6;ljt f&#xF6;r&#xE4;ndringar i microbiomet i sputum vid antibiotikaanv&#xE4;nding, men endast ett f&#xE5;tal studier har kartlagt mikrobiomf&#xF6;r&#xE4;ndringar i sputum hos r&#xF6;kare. Det f&#xF6;religger inga studier d&#xE4;r mikrobiomet i lunga kartlagts hos patienter med biomass-orsakad KOL.Vi anser att &#xF6;kad kunskap om lungans microbiom i relation till biomass-orsakad KOL utg&#xF6;r en viktig ing&#xE5;ngsport f&#xF6;r att utveckla behandlingsstrategier f&#xF6;r denna stora sjukdomsgrupp i l&#xE5;g- och medelinkomstl&#xE4;nder.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Karolinska Institutet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2021-01-01" type="1"></activity-date>
  <activity-date iso-date="2022-12-31" type="3"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="IN" percentage="100">
   <narrative xml:lang="EN">India</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="1" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2020-01-01"></period-start>
   <period-end iso-date="2020-12-28"></period-end>
   <value currency="USD" value-date="2020-01-01">42346.6562428744</value>
  </budget>
  <budget>
   <period-start iso-date="2021-01-01"></period-start>
   <period-end iso-date="2021-12-28"></period-end>
   <value currency="USD" value-date="2021-01-01">42346.6562428744</value>
  </budget>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="USD" value-date="2020-01-28">42346.6562428744</value>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-10-20"></transaction-date>
   <value currency="USD" value-date="2020-10-20">84693.3124857487</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-01-28"></transaction-date>
   <value currency="USD" value-date="2021-01-28">14115.5520809581</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
